Author's response to reviews

Title: The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period

Authors:

Peter Weeke (pw@heart.dk)
Charlotte Andersson (ca@heart.dk)
Emil L Fosbøl (elf@heart.dk)
Bente Brendorp (bb@heart.dk)
Lars Køber (lk@heart.dk)
Arya M Sharma (sharma@obesitynetwork.ca)
Nick Finer (n.finer@ucl.ac.uk)
Philip T James (JeanHJames@aol.com)
Ian D Caterson (l.caterson@mmb.usyd.edu.au)
Richard A Rode (Richard.A.Rode@abbott.com)
Christian Torp-Pedersen (ctp@heart.dk)

Version: 3 Date: 20 August 2009

Author's response to reviews:

Cover letter

Enclosed please find the manuscript ‘Sibutramine and its impact on lipids in cardiovascular high risk patients with and without type 2 diabetes - an analysis from the SCOUT lead-in period’. The data presented are gathered on 10 742 high-risk obese individuals showing the link between the anti-obesity drug ‘sibutramine’, and the following changes in lipids for patients with and without type-2-diabetes. We hope that you will find this manuscript suitable for publication in ‘BMC Endocrine Disorders.

All authors have participated in the planning and analysis of the study and resulting paper. Furthermore, all authors have read and approved the version for submission. The data presented in the manuscript are original and have not been published previously, nor have we submitted this manuscript elsewhere.

Yours sincerely

Peter Weeke